Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2005-10-20
2008-10-28
Balasubram, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S374000, C514S247000, C514S256000, C514S266100, C514S308000, C514S311000, C514S362000, C514S363000, C514S364000, C514S365000, C514S367000, C514S372000, C514S373000, C514S375000, C514S378000, C514S383000, C514S396000, C514S406000, C514S410000, C514S438000, C514S439000, C546S152000, C546S139000, C546S266000, C548S235000, C548S128000, C548S131000, C548S136000, C548S146000, C548S206000, C548S215000, C548S240000, C548S262200, C548S304400, C548S341100, C548S452000, C544S224000, C544S283000, C544S335000, C544S
Reissue Patent
active
RE040558
ABSTRACT:
The use of diaryl acid derivatives of formula (I)or pharmaceutically acceptable salts, N-oxides, hydrates or solvates thereof, wherein the variables shown are defined in the disclosure, and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.
REFERENCES:
patent: 4794188 (1988-12-01), Musser et al.
patent: 6290973 (2001-09-01), Hawkins et al.
patent: 6376512 (2002-04-01), Jayyosi et al.
patent: 7005440 (2006-02-01), Jayyosi et al.
patent: 248922 (1987-03-01), None
patent: 0 520 723 (1992-12-01), None
patent: 0 657 422 (1995-06-01), None
patent: 0 845 451 (1998-06-01), None
patent: WO 87/05510 (1987-09-01), None
patent: WO 97/27847 (1997-08-01), None
patent: WO 97/27857 (1997-08-01), None
patent: WO 97/28137 (1997-08-01), None
patent: WO 97/28149 (1997-08-01), None
patent: WO 98/27974 (1998-07-01), None
patent: WO 99/08501 (1999-02-01), None
patent: WO 99/11255 (1999-03-01), None
patent: WO 99/15520 (1999-04-01), None
patent: WO 99/16758 (1999-04-01), None
patent: WO 99/20275 (1999-04-01), None
patent: WO 00/64876 (2000-11-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
Jones A.B., Medical Research RReviews, vol. 21, No. 6, 540552, 2001.
Kozikowski et al, Tetrahedron Lett.28/43,5125-8(1987), also cited as Chem.Abstract 110:56678.
Co-pending U.S. Application No. 09/724,496, filed on Nov. 28, 2000.
Picard et al., PubMed Abstr.: 12055342: “PPAR gama and Glucose Homeostasis,” Annu. Rev. Nutr., 22, 167-197 (2002).
Molavi et al. PubMed Abstr.: 12000972: “PPAR Ligands as . . . another Pandoras Box,” J. Cardiov. Pharm. Ther., Jan. 7, 7/1, 1-8 (2002).
Kozikowski et al., Chem Abstr., 110:56678; also cited as Tetrahedroon Lett., 28/43, 5125-28 (1987).
Kahovcova et al., Chem. Abstr., 111:115036; also cited as CS 248922 (1987).
Bloomgarden, Z., “Insulin Resistance: Current Concepts,” Clinical Therapeutics, vol. 20, No. 2, pp. 216-231 (1998).
Torra, I.P. et al., “Peroxisome proliferator-activated receptor alpha in metabolic disease, Inflammation, atherosclerosis and aging,” Current Opinion in Lipidology, vol. 10, pp. 151-159 (1999).
Bobko Mark
Caulfield Thomas J.
Groneberg Robert D.
Jayyosi Zaid
Kelley Michael F.
Balasubram Venkataraman
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Sanofi-Aventis Deutschland GmbH
LandOfFree
Therapeutic uses of di-aryl acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic uses of di-aryl acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of di-aryl acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4009731